We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Hartford Financial Services
HIG
$38.9B
| $34.2M | 0.09% |
887,483
-23,200
| -3% | -$884K |
|
252
Crown Castle
CCI
$33.9B
| $34.2M | 0.09% |
204,159
-269,850
| -57% | -$43.5M |
|
|
ARCH
253
DELISTED
Arch Resources, Inc.
ARCH
| $34.1M | 0.09% |
1,200,170
+1,050,170
| +700% | +$32.7M |
|
254
Lear
LEA
$6.21B
| $34.1M | 0.09% |
+312,628
| New | +$31.1M |
|
255
Synchrony
SYF
$25.7B
| $33.8M | 0.09% |
1,525,963
+1,049,117
| +220% | +$20.4M |
|
256
Visteon
VC
$2.81B
| $33.7M | 0.09% |
492,162
+314,891
| +178% | +$19.8M |
|
257
Avery Dennison
AVY
$13.3B
| $33.7M | 0.09% |
295,404
+289,679
| +5,060% | +$31.8M |
|
258
Constellation Brands
STZ
$22.4B
| $33.6M | 0.09% |
192,167
+100
| +0.1% | +$16.7K |
|
259
Synopsys
SNPS
$77.3B
| $33.5M | 0.09% |
172,000
+600
| +0.4% | +$99K |
|
260
Flowserve
FLS
$10.2B
| $33.5M | 0.09% |
1,175,581
+135,477
| +13% | +$3.61M |
|
261
SPDR Gold Trust
GLD
$132B
| $33.5M | 0.09% |
200,000
-50,000
| -20% | -$8.06M |
|
262
Kinder Morgan
KMI
$69.9B
| $33.5M | 0.09% |
2,205,700
+462,300
| +27% | +$7.03M |
|
|
NBP
263
NovaBridge Biosciences American Depositary Shares
NBP
$191M
| $33.4M | 0.09% |
1,117,317
+117,317
| +12% | +$2.43M |
|
264
Fox Class A
FOXA
$24.8B
| $33.4M | 0.09% |
1,245,430
+361,800
| +41% | +$9.77M |
|
265
Global Payments
GPN
$24.1B
| $33.4M | 0.09% |
196,902
-170,300
| -46% | -$28.3M |
|
266
Travere Therapeutics
TVTX
$5.21B
| $33.4M | 0.09% |
1,634,500
+592,702
| +57% | +$9.44M |
|
|
FLG
267
Flagstar Bank National Association
FLG
$5.95B
| $33.3M | 0.09% |
1,086,866
+300,066
| +38% | +$9.02M |
|
268
Cognizant
CTSH
$25.3B
| $33M | 0.08% |
580,850
-42,700
| -7% | -$2.29M |
|
269
Public Storage
PSA
$61B
| $33M | 0.08% |
171,792
| – | – |
|
270
Ashland
ASH
$3.31B
| $32.9M | 0.08% |
476,503
+75,000
| +19% | +$4.66M |
|
271
Applied Materials
AMAT
$434B
| $32.9M | 0.08% |
544,302
+84,449
| +18% | +$4.56M |
|
272
MSCI
MSCI
$41.5B
| $32.8M | 0.08% |
98,200
+1,100
| +1% | +$356K |
|
273
Idexx Laboratories
IDXX
$46.4B
| $32.5M | 0.08% |
98,298
+25,168
| +34% | +$7.29M |
|
274
ResMed
RMD
$32.4B
| $32.2M | 0.08% |
167,494
-96,420
| -37% | -$15.8M |
|
275
Verisk Analytics
VRSK
$25.1B
| $31.9M | 0.08% |
187,200
+1,000
| +0.5% | +$158K |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.